pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC
Fulcrum Therapeutics
Fulcrum Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
26 Landsdowne St, Cambridge, Massachusetts 02139, US HQ
2016 Founded
73 Employees
Public company Type
FULC · NYSE Ticker
Company details
- Status
- Public
- HQ
- 26 Landsdowne St, Cambridge, Massachusetts 02139, US
- Founded
- 2016
- Employees
- 73
- Programs
- 12
- Drugs
- 8
- Patents
- 11
Fulcrum Therapeutics projects
3 ClinicalTrials.gov programs sponsored by Fulcrum Therapeutics.
Fulcrum Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does Fulcrum Therapeutics have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.